Examples
Worked examples
- Is an instance
A university investigator wants to compare two FDA-approved antihypertensive drugs, each used strictly within its approved dose, route, and indication, to see which controls blood pressure better in a general adult population. The study isn't intended to change either drug's labeling, doesn't raise the risk profile beyond approved use, and will run under normal IRB review and informed consent. It qualifies for the 312.2(b) exemption, so no IND is needed.
- Is an instance
A hospital pharmacy department studies whether an FDA-approved oral antibiotic, given at its approved dose and route, is as effective when administered on a different dosing schedule that is still within the approved labeling's flexibility, purely to inform internal formulary and nursing workflow decisions with no intent to seek a labeling change. Because the study doesn't touch indication, doesn't increase risk, and isn't promotional, it is exempt from IND requirements under 312.2(b).
Counter-examples
Looks similar, but isn't
- Not an instance
A study proposes to use an FDA-approved oncology drug at a substantially higher dose than its approved labeling to treat a cancer type it isn't approved for. This fails at least two 312.2(b) conditions at once — it targets a new indication and it involves a dose that significantly increases risk relative to approved use — so the exemption does not apply and a full IND (typically a research/Investigator IND) is required, even though the drug itself is already FDA-approved for a different use.
- Not an instance
A manufacturer sponsors a study of its own approved drug, conducted entirely within approved labeling, but designs promotional materials around the results before the study is complete, intending to use the findings to support advertising claims beyond the approved indication. Even though the clinical conduct of the study looks exemption-eligible on its face, the promotional intent independently fails the 312.2(b) condition barring studies intended to support drug advertising, so the exemption does not apply.
Editorial commentary
An IND exemption under 21 CFR 312.2(b) is the regulatory pathway that allows a clinical investigation of a drug already lawfully marketed in the United States to proceed without an Investigational New Drug (IND) application, provided the study meets every condition the rule sets out. It is a bright-line determination a sponsor (which, for an investigator-initiated study, is often the investigator personally) must make and document before enrolling subjects — there is no case-by-case FDA pre-clearance step for claiming the exemption itself, though FDA can and does challenge an exemption claim after the fact if a study doesn’t actually meet the criteria. See CASRAI’s Investigational New Drug (IND) entry for the broader IND framework this exemption sits inside.
The five conditions under 21 CFR 312.2(b)(1)
A study of a lawfully marketed drug is exempt from IND requirements only if it satisfies all of the following simultaneously:
- No new indication or significant labeling/advertising change. The investigation is not intended to be reported to FDA in support of a new indication for use, or to support any other significant change in the labeling of the drug.
- No significant increase in risk. The investigation is not intended to support a significant change in the advertising for the product, and does not involve a route of administration, dosage level, use in a patient population, or other factor that significantly increases the risks (or decreases the acceptability of the risks) associated with the drug’s approved use.
- IRB and informed consent compliance. The investigation is conducted in compliance with the requirements for institutional review under 21 CFR Part 56 and with the requirements for informed consent under 21 CFR Part 50.
- No promotional intent. The investigation is conducted in compliance with the requirements of 21 CFR 312.7, meaning it is not intended to promote or commercialize the drug for an investigational use for which it lacks approval.
- Already lawfully marketed. The drug under study is lawfully marketed in the United States, which is the threshold condition for 312.2(b) to apply at all — an unapproved drug or biologic cannot use this exemption regardless of how the study is designed.
Because the conditions are conjunctive, a study that satisfies four of the five but fails one — most commonly the risk-increase or new-indication conditions — does not qualify for the exemption and needs a full IND.
Why this determination matters operationally
Getting the 312.2(b) determination right has real consequences for study timelines and sponsor obligations. A study that correctly qualifies for the exemption avoids the IND application itself, the 30-calendar-day FDA review window, and the ongoing Subpart D sponsor obligations (safety reporting, annual reports, investigator qualification records) that attach to an active IND. A study that incorrectly claims the exemption — enrolling subjects without an IND when one was actually required — exposes the sponsor and institution to a clinical hold, required corrective action, and potential regulatory findings on inspection. Because the determination sits with the sponsor rather than requiring FDA sign-off in advance, institutions typically route it through their IRB or a research-compliance office as part of protocol review, precisely because the conditions require judgment calls (most often on whether a dose, route, or population change “significantly increases risk”) rather than a mechanical checklist.
Common edge cases
The most frequent source of a wrong exemption call is the risk-increase condition, since “significantly increases risk” is not defined by a bright-line threshold in the regulation itself — it requires a substantive risk assessment relative to the drug’s approved use, typically informed by the approved labeling, known adverse event profile, and how far the proposed dose, route, or population departs from it. A second frequent trigger is intent: a study that is clinically low-risk but is explicitly designed to generate data for a future labeling supplement or promotional claim fails the exemption on the new-indication or promotional-intent conditions even if the clinical risk profile looks unchanged. Comparative-effectiveness and pragmatic trials that stay strictly within each drug’s approved use are the clearest exemption-eligible case; dose-escalation, off-label indication, and vulnerable-population studies are the clearest cases requiring a full IND.
Relationship to other IND mechanisms
A study that does not qualify for the 312.2(b) exemption generally proceeds under either a standard IND filed by a commercial sponsor, or a research (Investigator) IND filed by a sponsor-investigator who both initiates and conducts the study. The exemption applies only to drugs; the parallel device framework, the Investigational Device Exemption (IDE) under 21 CFR Part 812, has its own separate significant-risk/nonsignificant-risk determination and is not governed by 312.2(b) at all. See also CASRAI’s guide to Pre-IND meetings for how sponsors who are uncertain whether a planned study qualifies for the exemption can seek informal FDA feedback before finalizing the protocol.
Machine-readable encodings
Use in your systems
<role vocab="credit"
vocab-identifier="https://casrai.org/dictionary/"
vocab-term="IND Exemption (21 CFR 312.2(b))"
vocab-term-identifier="https://casrai.org/dictionary/term/ind-exemption-21-cfr-312-2b" />{
"@context": "https://schema.org",
"@type": "DefinedTerm",
"@id": "https://casrai.org/dictionary/term/ind-exemption-21-cfr-312-2b",
"name": "IND Exemption (21 CFR 312.2(b))",
"identifier": "https://casrai.org/dictionary/term/ind-exemption-21-cfr-312-2b",
"description": "The regulatory determination, made by a sponsor under 21 CFR 312.2(b), that a clinical investigation of a drug already lawfully marketed in the United States does not require an Investigational New Drug (IND) application because the study meets all five conditions in the rule: it is not intended to support a new indication or a significant labeling/advertising change, it does not significantly increase the risk (or decrease the acceptability of risk) associated with the drug's approved use, it is conducted in compliance with IRB review (21 CFR Part 56) and informed consent (21 CFR Part 50) requirements, it is not intended to promote the drug for an unapproved use, and it does not involve a route of administration, dosage level, patient population, or other factor that significantly increases the risks associated with the drug's approved use. All conditions must be met simultaneously; failing any one of them means the study needs a full IND regardless of how the others resolve.",
"inDefinedTermSet": "https://casrai.org/dictionary/domain/clinical-research#set",
"url": "https://casrai.org/dictionary/term/ind-exemption-21-cfr-312-2b",
"sameAs": [],
"license": "https://creativecommons.org/licenses/by/4.0/",
"publisher": {
"@id": "https://casrai.org/#organization"
},
"dateModified": "2026-07-18T03:01:48",
"inLanguage": "en"
}
